Paraneoplastic syndromes

Revue Neurologique

Volumn 158, Issue 10 I, 2002, Pages 899-906

  Posner, J B ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIAMINOPYRIDINE; AUTOANTIBODY; BACLOFEN; CLONAZEPAM; CORTICOTROPIN; CYCLOPHOSPHAMIDE; CYPROHEPTADINE; DIAZEPAM; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; PROTEIN A; STEROID;

ANTIBODY DETECTION; ANTIGEN RECOGNITION; CEREBELLUM DISEASE; HUMAN; HYPOTHESIS; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; MALIGNANT NEOPLASTIC DISEASE; MUSCLE DISEASE; NEUROLOGIC DISEASE; NEUROLOGICAL COMPLICATION; NEUROMUSCULAR JUNCTION DISORDER; PARANEOPLASTIC SYNDROME; PERIPHERAL NEUROPATHY; PLASMAPHERESIS; REVIEW; SPINAL CORD DISEASE;

EID: 0036807667     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Albert ML, Austin LM, Darnell RB. (2000). Detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration. Ann Neurol, 47: 9-17.
2. Antoine JC, Mosnier JF, Absi L, Convers P, Honnorat J, Michel D. (1999). Carcinoma associated paraneoplastic peripheral neuropathies in patients with and without anti-onconeural antibodies. J Neurol Neurosurg Psychiatry, 67: 7-14.
3. Babikian VL, Stefansson K, Dieperink ME, et al. (1985). Paraneoplastic myelopathy: Antibodies against protein in normal spinal cord and underlying neoplasm. Letter to the editor. Lancet, 2: 49-50.
4. Bain PG, Motomura M, Newsom-Davis J, et al. (1996). Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology, 47: 678-683.
5. Barnett M, Prosser J, Sutton I, et al. (2001). Paraneoplastic brain stem encephalitis in a woman with anti-Ma2 antibody. J Neurol Neurosurg Psychiatry, 70: 222-225.
6. Bataller L, Graus F, Saiz A, Vilchez JJ. (2001). Spanish Opsoclonus MS. Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus. Brain, 124: 437-443.
7. Blumenthal D, Schochet S Jr., Gutmann L, Ellis B, Jaynes M, Dalmau J. (1998). Small-cell carcinoma of the lung presenting with paraneoplastic peripheral nerve microvasculitis and optic neuropathy. Muscle and Nerve, 21: 1358-1359.
8. Brown P, Marsden CD. (1999). The stiff man and stiff man plus syndromes. J Neurol, 246: 648-652.
9. Byrne T, Mason WP, Posner JB, Dalmau J. (1997). Spontaneous neurological improvement in anti-Hu associated encephalomyelitis. J Neurol Neurosurg Psychiatry, 62: 276-278.
10. Camerlingo M, Nemni R, Ferraro B, et al. (1998). Malignancy and sensory neuropathy of unexplained cause. Arch Neurol, 55: 981-984.
11. Cao Y, Abbas J, Wu X, Dooley J, Van Amburg AL. (1999). Anti-Yo positive paraneoplastic cerebellar degeneration associated with ovarian carcinoma: Case report and review of the literature. Gynecol Oncol, 75: 178-183.
12. Carpentier AF, Delattre JY. (2001). The Lambart-Eaton myasthenic syndrome. Clin Rev Allergy Immunol, 20: 155-158.
13. Carpentier AF, Rosenfeld MR, Delattre J-Y, Whalen RG, Posner JB, Dalmau J. (1998). DNA vaccination with HuD inhibits growth of a neuroblastoma in mice. Clin Cancer Res, 4: 2819-2824.
14. Chan KH, Vernino S, Lennon VA. (2001). ANNA-3 anti-neuronal nuclear antibody: Marker of lung cancer-related autoimmunity. Ann Neurol, 50: 301-311.
15. Chio A, Brignolio F, Meineri P, Rosso MG, Tribolo A, Schiffer D. (1988). Motor neuron disease and malignancies: Results of a population-based study. J Neurol, 235: 374-375.
16. Croteau D, Owainati A, Dalmau J, Rogers LR. (2001). Response to cancer therapy in a patient with a paraneoplastic choreiform disorder. Neurology, 57: 719-722.
17. Dalmau J, Furneaux HM, Rosenblum MK, Graus F, Posner JB. (1991). Detection of the anti-Hu antibody in specific regions of the nervous system and tumor from patients with paraneoplastic encephalomyelitis/sensory neuronopathy. Neurology, 41: 1757-1764.
18. Dalmau J, Graus F, Cheung N-KV, et al. (1995). Major histocompatibility proteins, anti-Hu antibodies, and paraneoplastic encephalomyelitis in neuroblastoma and small cell lung cancer. Cancer, 75: 99-109.
19. Dalmau J, Posner JB. (1994). Neurologic paraneoplastic antibodies (anti-Yo; anti-Hu; anti-Ri): The case for a nomenclature based on antibody and antigen specificity. Neurology, 44: 2241-2246.
20. Delbeke D, Martin WH. (2001). Positron emission tomography imaging in oncology. Radiol Clin North Am, 39: 883-917.
21. Erlington GM, Murray NM, Spiro SG, Newsom-Davis J. (1991). Neurological paraneoplastic syndromes in patients with small cell lung cancer. A prospective survey of 150 patients. J Neurol Neurosurg Psychiatry, 54: 764-767.
22. Furneaux HM, Reich L, Posner JB. (1990). Autoantibody synthesis in the central nervous system of patients with paraneoplastic syndromes. Neurology, 40: 1085-1091.
23. Golbe LI, Miller DC, Duvoisin RC. (1989). Paraneoplastic degeneration of the substantia nigra with dystonia and Parkinsonism. Mov Disord, 4: 147-152.
24. Goldstein SM, Syed NA, Milam AH, Maguire AM, Lawton TJ, NICHOLS CW. (1999). Cancer-associated retinopathy. Arch Ophthalmol, 117: 1641-1645.
25. Graus F, Keime-Guibert F, Reñe R, et al. (2001). Anti-Hu-associated paraneoplastic encephalomyelitis: Analysis of 200 patients. Brain, 124: 1138-1148.
26. Greenlee JE. (2000). Cytotoxic T cells in paraneoplastic cerebellar degeneration. Ann Neurol, 47: 4-5.
27. Gultekin SH, Rosenfeld MR, Voltz R, Eichen J, Posner JB, Dalmau J. (2000). Paraneoplastic limbic encephalitis: Neurological symptoms, immunological findings and tumour association in 50 patients. Brain, 123: 1481-1494.
28. Jensen KB, Dredge BK, Stefani G, et al. (2000). Nova-1 regulates neuron-specific alternative splicing and is essential for neuronal viability. Neuron, 25: 359-371.
29. Keime-Guibert F, Graus F, Fleury A, et al. (2000). Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, Anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry, 68: 479-482.
30. Koralnik IJ, Du Pasquier RA, Kuroda MJ, et al. (2002). Association of prolonged survival in HLA-A2+ progressive multifocal leukoencephalopathy patients with a CTL response specific for a commonly recognized JC virus epitope. J Immunol, 168: 499-504.
31. Lachance DH, O'Neill BP, Harper CM, Jr, Banks PM, Cascino TL. (1991). Paraneoplastic brachial plexopathy in a patient with Hodgkin's disease. Mayo Clin Proc, 66: 97-101.
32. Lahrmann H, Albrecht G, Drlicek M, et al. (2001). Acquired neuromyotonia and peripheral neuropathy in a patient with Hodgkin's disease. Muscle and Nerve, 24: 834-838.
33. Lee HR, Lennon VA, Camilleri M, Prather CM. (2001). Paraneoplastic gastrointestinal motor dysfunction: Clinical and laboratory characteristics. Am J Gastroenterol, 96: 373-379.
34. Levin MI, Mozaffar T, Al-Lozi MT, Pestronk A. (1998). Paraneoplastic necrotizing myopathy - Clinical and pathologic features. Neurology, 50: 764-767.
35. Levy EI, Harris AE, Omalu BI, Hamilton RL, Branstetter BF, Pollack IF. (2001). Sudden death from fulminant acute cerebellitis. Pediatr Neurosurg, 35: 24-28.
36. Lieberman FS, Odel J, Hirsch J, Heinemann M, Michaeli J, Posner J. (1999). Bilateral optic neuropathy with IgGkappa multiple myeloma improved after myeloablative chemotherapy. Neurology, 52: 414-416.
37. Lienhardt A, Grossman AB, Dacie JE, et al. (2001). Relative contributions of inferior petrosal sinus sampling and pituitary imaging in the investigation of children and adolescents with ACTH-dependent Cushing's syndrome. J Clin Endocrinol Metab, 86: 5711-5714.
38. Lipton RB, Galer BS, Dutcher JP, et al. (1987). Quantitative sensory testing demonstrates that subclinical sensory neuropathy is prevalent in patients with cancer. Arch Neurol, 44: 944-946.
39. Lisak RP, Mitchell M, Zweiman B, Orrechio E, Asbury AK. (1977). Guillain-Barre syndrome and Hodgkin's disease: Three cases with immunological studies. Ann Neurol, 1: 72-78.
40. Maddison P, Newsom-Davis J, Mills KR, Souhami RL. (1999). Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma (letter). Lancet, 353: 117-118.
41. Maeda T, Maeda A, Maruyama I, et al. (2001). Mechanisms of photo-receptor cell death in cancer-associated retinopathy. Invest Ophthalmol Vis Sci, 42: 705-712.
42. Meglic B, Graus F, Grad A. (2001). Anti-Yo-associated paraneoplastic cerebellar degeneration in a man with gastric adenocarcinoma. J Neurol Sciences, 185: 135-138.
43. Okano HJ, Park WY, Corradi JP, Darnell RB. (1999). The cytoplasmic Purkinje onconeural antigen cdr2 down-regulates c-Myc function: Implications for neuronal and tumor cell survival. Genes Dev 13: 2087-2097.
44. Pascual J, Sanchez-Pernaute R, Berciano J, Calleja J. (1994). Paraneoplastic myotonia. Muscle Nerve, 17: 694-695.
45. Peltola J, Hietaharju A, Rantala I, Lehtinen T, Haapasalo H. (1998). A reversible neuronal antibody (anti-Tr) associated paraneoplastic cerebellar degeneration in Hodgkin's disease. Acta Neurol Scand, 98: 360-363.
46. Posner JB. (1995). Neurologic Complications of Cancer. Philadelphia: F.A. Davis, XXX
47. Rees JH, Hain SF, Johnson MR, et al. (2001). The role of ((18)F) fluoro-2-deoxyglucose-PET scanning in the diagnosis of paraneoplastic neurological disorders. Brain, 124: 2223-2231.
48. Rosenfeld MR, Eichen JG, Wade DF, Posner JB, Dalmau J. (2001). Molecular and clinical diversity in paraneoplastic immunity to Ma proteins. Ann Neurol, 50: 339-348.
49. Rudnicki SA, Dalmau J. (2000). Paraneoplastic syndromes of the spinal cord, nerve, and muscle. Muscle and Nerve, 23: 1800-1818.
50. Saiz A, Dalmau J, Butler MH, et al. (1999a). Anti-amphiphysin I antibodies in patients with paraneoplastic neurological disorders associated with small cell lung carcinoma. J Neurol Neurosurg Psychiatry, 66: 214-217.
51. Saiz A, Graus F, Dalmau J, Pifarré A, Marín C, Tolosa E. (1999b). Detection of 14-3-3 brain protein in the cerebrospinal fluid of patients with paraneoplastic neurological disorders. Ann Neurol, 46: 774-777.
52. Schneider C, Gold R, Reiners K, Toyka KV. (2001). Mycophenolate mofetil in the therapy of severe myasthenia gravis. Eur Neurol, 46: 79-82.
53. Schold SC, Cho ES, Somasundaram M, Posner JB. (1979). Subacute motor neuronopathy: A remote effect of lymphoma. Ann Neurol, 5: 271-287.
54. Scully RE, Mark EJ, McNeely WF, et al. (1988). Case records of the Massachusetts General Hospital. Case 14-1988. N Engl J Med, 318: 903-915.
55. Silverman IE. (1999). Paraneoplastic stiff limb syndrome. J Neurol Neurosurg Psychiatry, 67: 126-127.
56. Stockton D, Doherty VR, Brewster DH. (2001). Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: A Scottish population-based cohort study. Br J Cancer, 85: 41-45.
57. Sutton I, Winer JB. (2002). The immunopathogenesis of paraneoplastic neurological syndromes 3. Clin Sci (Lond), 102: 475-486.
58. Szabo A, Dalmau J, Manley G, et al. (1991). HuD, a paraneoplastic encephalomyelitis antigen, contains RNA-binding domains and is homologous to Elav and Sex-lethal. Cell, 67: 325-333.
59. Tanaka K, Tanaka M, Inuzuka T, Nakano R, Tsuji S. (1999). Cytotoxic T lymphocyte-mediated cell death in paraneoplastic sensory neuronopathy with anti-Hu antibody. J Neurological Sciences, 163: 159-162.
60. Vernino S, Auger RG, Emslie-Smith AM, Harper CM, Lennon VA. (1999). Myasthenia, thymoma, presynaptic antibodies, and a continuum of neuromuscular hyperexcitability. Neurology, 53: 1233-1239.
61. Vernino S, Lennon VA. (2000). New Purkinje cell antibody (PCA-2): Marker of lung cancer-related neurological autoimmunity. Ann Neurol, 47: 297-305.
62. Verschuuren J, Chuang L, Rosenblum MK, et al. (1996). Inflammatory infiltrates and complete absence of Purkinje cells in anti-Yo associated paraneoplastic cerebellar degeneration. Acta Neuropathol, 91: 519-525.
63. Vigliani MC, Palmucci L, Polo P, et al. (2001). Paraneoplastic opsoclonus-myoclonus associated with renal cell carcinoma and responsive to tumour ablation. J Neurol Neurosurg Psychiatry, 70: 814-815.
64. Vincent A. (2000). Understanding neuromyotonia. Muscle and Nerve, 23: 655-657.
65. Younger DS. (2000). Motor neuron disease and malignancy. Muscle and Nerve, 23: 658-660.
66. Yu ZY, Kryzer TJ, Griesmann GE, Kim KK, Benarroch EE, Lennon VA. (2001). CRMP-5 neuronal autoantibody: Marker of lung cancer and thymoma-related autoimmunity. Ann Neurol, 49: 146-154.